Literature DB >> 33318302

TLR2 regulates angiotensin II-induced vascular remodeling and EndMT through NF-κB signaling.

Ke Lin1,2, Wu Luo1, Jueqian Yan1, Siyuan Shen1,2, Qirui Shen1, Jun Wang3, Xinfu Guan4, Gaojun Wu2, Weijian Huang2, Guang Liang1,2,4.   

Abstract

Excessive vascular remodeling has been shown in hypertensive patients. In experimental models of hypertensive vascular injury, such as angiotensin II (Ang II) challenged mice, toll like receptor 2 (TLR2) initiates inflammatory responses. More recently, studies have reported atypical endothelial to mesenchymal transition (EndMT) in vascular injuries and inflammatory conditions. Here, we aimed to investigate whether TLR2 mediates Ang II-induced vascular inflammation and initiates EndMT. In a mouse model of angiotensin II-induced hypertension, we show that aortas exhibit increased medial thickening, fibrosis, and features of EndMT. These alterations were not observed in TLR2 knockout mice in response to Ang II. TLR2 silencing in cultured endothelial cells confirmed the essential role of TLR2 in Ang II-induced inflammatory factor induction, and EndMT-associated phenotypic change. Mechanistically, we found Ang II activates nuclear factor-κB signaling, inducing pro-inflammatory cytokine production, and mediates EndMT in both cultured endothelial cells and in mice. These studies illustrate a novel role of TLR2 in regulating Ang II-induced deleterious vascular remodeling through the induction of EndMT. The studies also suggest that TLR2 may be targeted to alleviate hypertension-associated vascular injury.

Entities:  

Keywords:  NF-κB; TLR2; angiotensin II; endothelial to mesenchymal transition; vascular remodeling

Mesh:

Substances:

Year:  2020        PMID: 33318302      PMCID: PMC7880316          DOI: 10.18632/aging.202290

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  43 in total

1.  IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner.

Authors:  Monika Maleszewska; Jan-Renier A J Moonen; Nicolette Huijkman; Bart van de Sluis; Guido Krenning; Martin C Harmsen
Journal:  Immunobiology       Date:  2012-06-06       Impact factor: 3.144

2.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 3.  Endothelial-to-Mesenchymal Transition.

Authors:  Joyce Bischoff
Journal:  Circ Res       Date:  2019-04-12       Impact factor: 17.367

Review 4.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.

Authors:  S Kim; H Iwao
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

5.  Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling.

Authors:  Qingwei Zhao; Minako Ishibashi; Ken-ichi Hiasa; Chunyan Tan; Akira Takeshita; Kensuke Egashira
Journal:  Hypertension       Date:  2004-07-19       Impact factor: 10.190

6.  Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation.

Authors:  Shengban You; Jianchang Qian; Gaojun Wu; Yuanyuan Qian; Zhengxian Wang; Taiwei Chen; Jingying Wang; Weijian Huang; Guang Liang
Journal:  Phytomedicine       Date:  2019-05-11       Impact factor: 5.340

7.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

8.  Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.

Authors:  Lian Xu; Mengxia Fu; Dongrui Chen; Weiqing Han; Michael C Ostrowski; Paul Grossfeld; Pingjin Gao; Maoqing Ye
Journal:  BMB Rep       Date:  2019-10       Impact factor: 4.778

9.  Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm.

Authors:  Huimin Yan; Bing Cui; Xiaowei Zhang; Xiaoming Fu; Jun Yan; Xiaoxing Wang; Xiaoxi Lv; Zhong Chen; Zhuowei Hu
Journal:  Acta Pharm Sin B       Date:  2015-04-07       Impact factor: 11.413

Review 10.  Independent regulation of renin-angiotensin-aldosterone system in the kidney.

Authors:  Akira Nishiyama; Hiroyuki Kobori
Journal:  Clin Exp Nephrol       Date:  2018-03-29       Impact factor: 2.801

View more
  2 in total

1.  Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.

Authors:  Dan Li; Ying-Ying Guo; Xian-Feng Cen; Hong-Liang Qiu; Si Chen; Xiao-Feng Zeng; Qian Zeng; Man Xu; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2021-12-16       Impact factor: 7.169

Review 2.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.